Details

Autor(en) / Beteiligte

• Neubauer, Stefan
• Kolm, Paul
• Ho, Carolyn Y.
• Kwong, Raymond Y.
• Desai, Milind Y.
• Dolman, Sarahfaye F.
• Appelbaum, Evan
• Desvigne-Nickens, Patrice
• DiMarco, John P.
• Friedrich, Matthias G.
• Geller, Nancy
• Harper, Andrew R.
• Jarolim, Petr
• Jerosch-Herold, Michael
• Kim, Dong-Yun
• Maron, Martin S.
• Schulz-Menger, Jeanette
• Piechnik, Stefan K.
• Thomson, Kate
• Zhang, Cheng
• Watkins, Hugh
• Weintraub, William S.
• Kramer, Christopher M.
• Mahmod, Masliza
• Jacoby, Daniel
• White, James
• Chiribiri, Amedeo
• Helms, Adam
• Choudhury, Lubna
• Michels, Michelle
• Bradlow, William
• Salerno, Michael
• Heitner, Stephen
• Prasad, Sanjay
• Mohiddin, Saidi
• Swoboda, Peter
• Mahrholdt, Heiko
• Bucciarelli-Ducci, Chiara
• Weinsaft, Jonathan
• Kim, Han
• McCann, Gerry
• van Rossum, Albert
• Williamson, Eric
• Flett, Andrew
• Dawson, Dana
• Mongeon, F. Pierre
• Olivotto, Iacopo
• Crean, Andrew
• Owens, Anjali
• Anderson, Lisa
• Biagini, Elena
• Newby, David
• Berry, Colin
• Kim, Bette
• Larose, Eric
• Abraham, Theodore
• Sherrid, Mark
• Nagueh, Sherif
• Rimoldi, Ornella
• Elstein, Eleanor
• Autore, Camillo

Titel

Distinct Subgroups in Hypertrophic Cardiomyopathy in the NHLBI HCM Registry

Ist Teil von

• Journal of the American College of Cardiology, 2019-11, Vol.74 (19), p.2333-2345

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2019

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• The HCMR (Hypertrophic Cardiomyopathy Registry) is a National Heart, Lung, and Blood Institute–funded, prospective registry of 2,755 patients with hypertrophic cardiomyopathy (HCM) recruited from 44 sites in 6 countries. The authors sought to improve risk prediction in HCM by incorporating cardiac magnetic resonance (CMR), genetic, and biomarker data. Demographic and echocardiographic data were collected. Patients underwent CMR including cine imaging, late gadolinium enhancement imaging (LGE) (replacement fibrosis), and T1 mapping for measurement of extracellular volume as a measure of interstitial fibrosis. Blood was drawn for the biomarkers N-terminal pro–B-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin T (cTnT), and genetic analysis. A total of 2,755 patients were studied. Mean age was 49 ± 11 years, 71% were male, and 17% non-white. Mean ESC (European Society of Cardiology) risk score was 2.48 ± 0.56. Eighteen percent had a resting left ventricular outflow tract (LVOT) gradient ≥30 mm Hg. Thirty-six percent had a sarcomere mutation identified, and 50% had any LGE. Sarcomere mutation–positive patients were more likely to have reverse septal curvature morphology, LGE, and no significant resting LVOT obstruction. Those that were sarcomere mutation negative were more likely to have isolated basal septal hypertrophy, less LGE, and more LVOT obstruction. Interstitial fibrosis was present in segments both with and without LGE. Serum NT-proBNP and cTnT levels correlated with increasing LGE and extracellular volume in a graded fashion. The HCMR population has characteristics of low-risk HCM. Ninety-three percent had no or only mild functional limitation. Baseline data separated patients broadly into 2 categories. One group was sarcomere mutation positive and more likely had reverse septal curvature morphology, more fibrosis, but less resting obstruction, whereas the other was sarcomere mutation negative and more likely had isolated basal septal hypertrophy with obstruction, but less fibrosis. Further follow-up will allow better understanding of these subgroups and development of an improved risk prediction model incorporating all these markers. [Display omitted]